Simpler two-drug HIV treatment with dolutegravir and lamivudine
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial studies whether taking dolutegravir plus lamivudine (a simpler two-drug regimen) can work as well as a standard three-drug HIV regimen for people who have reasons they can’t stay on the usual medicines. You may be offered free treatment if you meet the safety checks and can attend follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old and can join the study in person
- You have HIV-1 infection
- You’ve been on a standard three-drug HIV regimen for at least 24 weeks
- Your clinic can monitor your CD4 blood count multiple times in the first year and then every 6 months
- You must be able to follow the study schedule and sign consent for free treatment
- You cannot be allergic to dolutegravir or lamivudine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a simpler set of HIV medicines works for people with confirmed HIV-1 infection. It may help by making treatment easier to follow, while monitoring health with regular blood tests.
This study collects information from people with HIV who are either starting HIV treatment for the first time or switching from a three-drug regimen to a two-drug regimen with dolutegravir and lamivudine. The goal is to build a database to learn how well this dual therapy works in real-world practice.
This trial tests a two-drug HIV treatment for people who are new to HIV therapy and also have tuberculosis. It compares the two-drug combination to the standard three-drug regimen, with the goal of making treatment simpler while still being effective.
This trial tests better ways to manage HIV when the virus becomes resistant to dolutegravir (DTG), a key medicine. It is for people with high viral load despite being on DTG for at least six months.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
Hear when a new HIV/AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.